Research progress of novel serum marker Golgi protein 73 in clinical diagnosis and treatment of chronic hepatitis B_West China Medical Journal

Authors：

ZHANG Huan ,  LEI Xuezhong

Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding?author：

LEI Xuezhong, Email: 18980601317@163.com

Keywords：

Golgi protein 73; chronic hepatitis B; clinical value; research progress

DOI：

10.7507/1002-0179.202303089

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Serum marker Golgi protein 73 (GP73) is a type Ⅱ integral membrane protein located in cellular Golgi apparatus. GP73 not only processes proteins, but also participates in cell differentiation, intercellular signaling, and apoptosis. With the development of proteomics technology, GP73 has been used as a novel serum marker for detecting liver diseases. This article reviews the research progress of GP73 in the clinical diagnosis value and prognosis prediction of chronic hepatitis B in recent years, in order to provide new ideas for the diagnosis and treatment of patients with chronic hepatitis B.

Citation： ZHANG Huan, LEI Xuezhong. Research progress of novel serum marker Golgi protein 73 in clinical diagnosis and treatment of chronic hepatitis B. West China Medical Journal, 2023, 38(8): 1243-1246. doi: 10.7507/1002-0179.202303089 Copy

1.	Kladney RD, Bulla GA, Guo L, et al. GP73, a novel Golgi-localized protein upregulated by viral infection. Gene, 2000, 249(1/2): 53-65.
2.	Rosa-Ferreira C, Christis C, Torres IL, et al. The small G protein Arl5 contributes to endosome-to-Golgi traffic by aiding the recruitment of the GARP complex to the Golgi. Biol Open, 2015, 4(4): 474-481.
3.	Cao Z, Li Z, Wang H, et al. Algorithm of Golgi protein 73 and liver stiffness accurately diagnoses significant fibrosis in chronic HBV infection. Liver Int, 2017, 37(11): 1612-1621.
4.	Block TM, Comunale MA, Lowman M, et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci U S A, 2005, 102(3): 779-784.
5.	Gatselis NK, Zachou K, Giannoulis G, et al. Serum cartilage oligomeric matrix protein and Golgi protein-73: new diagnostic and predictive tools for liver fibrosis and hepatocellular cancer?. Cancers (Basel), 2021, 13(14): 3510.
6.	Dong M, Chen ZH, Li X, et al. Serum Golgi protein 73 is a prognostic rather than diagnostic marker in hepatocellular carcinoma. Oncol Lett, 2017, 14(5): 6277-6284.
7.	Liang R, Liu Z, Piao X, et al. Research progress on GP73 in malignant tumors. Onco Targets Ther, 2018, 11: 7417-7421.
8.	田霞. 血清 GDF-15、GP73、AFP 對肝細胞癌的診斷價值研究. 檢驗醫學與臨床, 2021, 18(16): 2438-2440.
9.	潘俊均, 黃仙圣, 岑偉明, 等. AFP、AFP-L3%、DCP 與 GP73 聯合檢測輔助診斷肝炎、肝癌臨床價值. 分子診斷與治療雜志, 2021, 13(10): 1579-1582.
10.	林召, 黨小軍, 侯智輝, 等. 血清 FFA、GP73 水平變化與慢性乙型肝炎患者病情程度的關聯性及臨床意義探討. 泰山醫學院學報, 2018, 39(8): 921-923.
11.	賈芳巖, 佘亞輝, 余明杰, 等. 慢性乙型肝炎患者血清 AFP-L3、GP73、AFP 水平變化及臨床價值研究. 國際檢驗醫學雜志, 2020, 41(12): 1527-1529.
12.	鄭志恒, 李維筠, 回振宇, 等. 聚乙二醇干擾素α-2a 聯合恩替卡韋治療慢性乙型肝炎患者療效及血清 Pygo2 和 GP73 水平變化. 實用肝臟病雜志, 2021, 24(1): 19-22.
13.	Peng Y, Zeng Q, Wan L, et al. GP73 is a TBC-domain Rab GTPase-activating protein contributing to the pathogenesis of non-alcoholic fatty liver disease without obesity. Nat Commun, 2021, 12(1): 7004.
14.	Wang L, Yao M, Liu S, et al. Serum Golgi protein 73 as a potential biomarker for hepatic necroinflammation in population with nonalcoholic steatohepatitis. Dis Markers, 2020, 2020: 6036904.
15.	Xu Z, Shen J, Pan X, et al. Predictive value of serum Golgi protein 73 for prominent hepatic necroinflammation in chronic HBV infection. J Med Virol, 2018, 90(6): 1053-1062.
16.	張曉坤, 司徒瑞儒. 甲胎蛋白、甲胎蛋白異質體 3 比率、高爾基體蛋白 73 聯合檢測在原發性肝癌診斷中的價值. 實用醫學雜志, 2021, 37(8): 1068-1071.
17.	袁吉磊, 黃輝, 成強. 血清前白蛋白聯合高爾基體蛋白 73 在肝病檢測及治療過程中的應用. 中國社區醫師, 2017, 33(3): 108-109.
18.	向琴. 血清 GP73 在 HBV 感染的慢性重型肝炎患者的表達水平及其對短期預后的預測價值. 南充: 川北醫學院, 2018.
19.	Yao M, Wang L, You H, et al. Serum GP73 combined AST and GGT reflects moderate to severe liver inflammation in chronic hepatitis B. Clin Chim Acta, 2019, 493: 92-97.
20.	許正鋸, 潘興南, 魏梅娟, 等. 慢性乙型肝炎病毒感染者恩替卡韋抗病毒治療前后血清高爾基體蛋白 GP73 的變化. 中華實驗和臨床感染病雜志(電子版), 2016, 10(3): 298-303.
21.	Liu L, Zhu J, Yang J, et al. GP73 facilitates hepatitis B virus replication by repressing the NF-κB signaling pathway. J Med Virol, 2020: 20.
22.	劉亞萍, 趙倩, 殷燕, 等. 慢性乙型肝炎患者血清 GP73、HA 水平與 HBV DNA 載量及肝功能的相關性研究. 臨床誤診誤治, 2019, 32(9): 48-53.
23.	Deveci O, Kaplan I, Tekin R, et al. Prognostic value of Golgi P73 and beta 2-microglobulin in patients with viral hepatitis B. Acta Biochim Pol, 2020, 67(1): 7-14.
24.	馬玲玉, 甄一寧, 羅云萍, 等. gp73 在小鼠肝纖維化肝組織中的表達及機制. 基礎醫學與臨床, 2020, 40(6): 771-776.
25.	羅雙艷, 何穎. 慢性乙肝患者肝臟炎癥及纖維化的影響因素及其與血清高爾基體蛋白 73 的相關性. 醫學信息, 2021, 34(15): 5-8.
26.	姚明解, 王雷婕, 關貴文, 等. 血清高爾基體蛋白 73 在輔助診斷慢性乙型肝炎患者中度以上肝損傷中的應用. 臨床肝膽病雜志, 2018, 34(4): 755-759.
27.	包海林, 謝群. HBV DNA、AFP、GP73 在慢性乙型肝炎病情嚴重程度及肝纖維化診斷中的應用價值研究. 海南醫學院學報, 2019, 25(9): 700-703.
28.	潘俊均, 黃仙圣, 岑偉明, 等. 不同病毒載量慢性乙型肝炎患者血清 AFP 與 GGT 和 GP73 變化及其臨床意義. 熱帶醫學雜志, 2022, 22(2): 179-183.
29.	申文曉. 慢性 HBV 感染者血清 GP73 和 IL-6 水平與肝纖維化指標的相關性. 桂林: 桂林醫學院, 2019.
30.	王利公, 趙珊, 陶慧, 等. 血清 AFP、GP73 和 AFP-L3 聯合檢測在慢性乙型肝炎診斷中的價值. 國際檢驗醫學雜志, 2019, 40(21): 2625-2628, 2632.
31.	杜婷. 血清高爾基體蛋白 73 對 ALT 正常或輕度升高的慢性乙型肝炎病毒感染者肝臟病變的預測價值. 銀川: 寧夏醫科大學, 2021.
32.	胡蕾蕾. 血清指標在慢性乙型肝炎患者肝纖維化診斷中的應用價值. 醫藥論壇雜志, 2021, 42(22): 43-46.
33.	王磊. 血清 SF、RBP4、GP73、resistin 水平檢測在慢性乙型肝炎患者病情評估中的應用價值. 實驗與檢驗醫學, 2018, 36(5): 752-754.
34.	奚經巧, 林枝, 趙春, 等. 肝功能正常慢性乙肝患者肝組織 GP73 表達與纖維化及炎癥分級關系. 實用預防醫學, 2018, 25(9): 1125-1128.
35.	黃冠華. 血清 GP73、CTLA4 水平與慢性乙型肝炎患者肝纖維化程度的相關性. 中國實用醫刊, 2021, 48(14): 49-52.
36.	Yang D, Yao M, Yan Y, et al. Deoxycholic acid upregulates serum Golgi protein 73 through activating NF-κB pathway and destroying Golgi structure in liver disease. Biomolecules, 2021, 11(2): 205.
37.	魯鳳民, 曾婉嘉, 文夏杰, 等. 慢性乙型肝炎抗病毒治療相關新型標志物及其臨床應用. 肝臟, 2019, 24(5): 483-486.
38.	范旭, 單珊, 劉立偉, 等. 血清高爾基糖蛋白 73 優于 APRI、FIB-4 對慢性 HBV 感染患者顯著纖維化的診斷. 現代消化及介入診療, 2020, 25(4): 529-532.
39.	Cao Z, Li Z, Wang Y, et al. Assessment of serum Golgi protein 73 as a biomarker for the diagnosis of significant fibrosis in patients with chronic HBV infection. J Viral Hepat, 2017, 24(Suppl 1): 57-65.
40.	Gatselis NK, Tornai T, Shums Z, et al. Golgi protein-73: a biomarker for assessing cirrhosis and prognosis of liver disease patients. World J Gastroenterol, 2020, 26(34): 5130-5145.
41.	馬世河, 劉文艷, 陳沖, 等. 血清 GP73 水平聯合腹部超聲檢查對慢性乙型肝炎肝纖維化程度的評估價值. 山東醫藥, 2022, 62(1): 25-29.
42.	Wei M, Xu Z, Pan X, et al. Serum GP73 - an additional biochemical marker for liver inflammation in chronic HBV infected patients with normal or slightly raised ALT. Sci Rep, 2019, 9(1): 1170.
43.	姜娜, 李瑛, 王光東, 等. 慢性乙肝不同炎癥分級患者的肝功能、纖維化指標和 GP73 檢測及臨床意義. 海南醫學, 2019, 30(24): 3155-3158.
44.	許正鋸, 潘興南, 魏梅娟, 等. 慢性 HBV 感染者血清 GP73 水平與白細胞介素 6 含量的相關性. 肝臟, 2017, 22(2): 136-139.
45.	劉沁雨, 常越, 張文, 等. GP73 預測慢性乙型肝炎患者肝硬化進展研究. 武警醫學, 2020, 31(4): 317-323.
46.	Liu T, Yao M, Liu S, et al. Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma. Oncotarget, 2017, 8(10): 16498-16506.
47.	Yao M, Wang L, Leung PSC, et al. The clinical significance of GP73 in immunologically mediated chronic liver diseases: experimental data and literature review. Clin Rev Allergy Immunol, 2018, 54(2): 282-294.
48.	Atilla A, Ta?k?n MH, Kazak Z, et al. GP73 level in patients with chronic hepatitis B: relationship with liver biopsy, levels of ALT, AST and HBV DNA. Indian J Pathol Microbiol, 2022, 65(1): 55-58.
49.	劉燕娜, 姚明解, 鄭素軍, 等. 血清高爾基體蛋白 73 在慢性肝病患者中的臨床應用. 中華肝臟病雜志, 2022, 30(1): 4-8.
50.	魏豐賢, 劉釗, 耿婕, 等. 高爾基體蛋白 73 與肝臟疾病的關系. 臨床肝膽病雜志, 2017, 33(8): 1595-1598.
51.	黎振威. 高爾基體蛋白 73 表達對 HBV 感染慢性肝病患者抗病毒治療后肝纖維化改善的預測價值. 銀川: 寧夏醫科大學, 2019.
52.	黨英男, 賈舒婷, 趙偉, 等. 慢性乙型肝炎患者血清 IL-17A、GP73 水平與肝功能指標及病情嚴重程度的關系分析. 現代生物醫學進展, 2020, 20(23): 4580-4584, 4570.
53.	程華, 鞠輝, 宋德順, 等. 慢性乙型肝炎患者血清血管生成素樣蛋白 2 和高爾基體蛋白 73 水平變化及其診斷顯著肝纖維化的效能分析. 實用肝臟病雜志, 2019, 22(4): 494-497.
54.	Xia Y, Zhang Y, Shen M, et al. Golgi protein 73 and its diagnostic value in liver diseases. Cell Prolif, 2019, 52(2): e12538.

1. Kladney RD, Bulla GA, Guo L, et al. GP73, a novel Golgi-localized protein upregulated by viral infection. Gene, 2000, 249(1/2): 53-65.
2. Rosa-Ferreira C, Christis C, Torres IL, et al. The small G protein Arl5 contributes to endosome-to-Golgi traffic by aiding the recruitment of the GARP complex to the Golgi. Biol Open, 2015, 4(4): 474-481.
3. Cao Z, Li Z, Wang H, et al. Algorithm of Golgi protein 73 and liver stiffness accurately diagnoses significant fibrosis in chronic HBV infection. Liver Int, 2017, 37(11): 1612-1621.
4. Block TM, Comunale MA, Lowman M, et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci U S A, 2005, 102(3): 779-784.
5. Gatselis NK, Zachou K, Giannoulis G, et al. Serum cartilage oligomeric matrix protein and Golgi protein-73: new diagnostic and predictive tools for liver fibrosis and hepatocellular cancer?. Cancers (Basel), 2021, 13(14): 3510.
6. Dong M, Chen ZH, Li X, et al. Serum Golgi protein 73 is a prognostic rather than diagnostic marker in hepatocellular carcinoma. Oncol Lett, 2017, 14(5): 6277-6284.
7. Liang R, Liu Z, Piao X, et al. Research progress on GP73 in malignant tumors. Onco Targets Ther, 2018, 11: 7417-7421.
8. 田霞. 血清 GDF-15、GP73、AFP 對肝細胞癌的診斷價值研究. 檢驗醫學與臨床, 2021, 18(16): 2438-2440.
9. 潘俊均, 黃仙圣, 岑偉明, 等. AFP、AFP-L3%、DCP 與 GP73 聯合檢測輔助診斷肝炎、肝癌臨床價值. 分子診斷與治療雜志, 2021, 13(10): 1579-1582.
10. 林召, 黨小軍, 侯智輝, 等. 血清 FFA、GP73 水平變化與慢性乙型肝炎患者病情程度的關聯性及臨床意義探討. 泰山醫學院學報, 2018, 39(8): 921-923.
11. 賈芳巖, 佘亞輝, 余明杰, 等. 慢性乙型肝炎患者血清 AFP-L3、GP73、AFP 水平變化及臨床價值研究. 國際檢驗醫學雜志, 2020, 41(12): 1527-1529.
12. 鄭志恒, 李維筠, 回振宇, 等. 聚乙二醇干擾素α-2a 聯合恩替卡韋治療慢性乙型肝炎患者療效及血清 Pygo2 和 GP73 水平變化. 實用肝臟病雜志, 2021, 24(1): 19-22.
13. Peng Y, Zeng Q, Wan L, et al. GP73 is a TBC-domain Rab GTPase-activating protein contributing to the pathogenesis of non-alcoholic fatty liver disease without obesity. Nat Commun, 2021, 12(1): 7004.
14. Wang L, Yao M, Liu S, et al. Serum Golgi protein 73 as a potential biomarker for hepatic necroinflammation in population with nonalcoholic steatohepatitis. Dis Markers, 2020, 2020: 6036904.
15. Xu Z, Shen J, Pan X, et al. Predictive value of serum Golgi protein 73 for prominent hepatic necroinflammation in chronic HBV infection. J Med Virol, 2018, 90(6): 1053-1062.
16. 張曉坤, 司徒瑞儒. 甲胎蛋白、甲胎蛋白異質體 3 比率、高爾基體蛋白 73 聯合檢測在原發性肝癌診斷中的價值. 實用醫學雜志, 2021, 37(8): 1068-1071.
17. 袁吉磊, 黃輝, 成強. 血清前白蛋白聯合高爾基體蛋白 73 在肝病檢測及治療過程中的應用. 中國社區醫師, 2017, 33(3): 108-109.
18. 向琴. 血清 GP73 在 HBV 感染的慢性重型肝炎患者的表達水平及其對短期預后的預測價值. 南充: 川北醫學院, 2018.
19. Yao M, Wang L, You H, et al. Serum GP73 combined AST and GGT reflects moderate to severe liver inflammation in chronic hepatitis B. Clin Chim Acta, 2019, 493: 92-97.
20. 許正鋸, 潘興南, 魏梅娟, 等. 慢性乙型肝炎病毒感染者恩替卡韋抗病毒治療前后血清高爾基體蛋白 GP73 的變化. 中華實驗和臨床感染病雜志(電子版), 2016, 10(3): 298-303.
21. Liu L, Zhu J, Yang J, et al. GP73 facilitates hepatitis B virus replication by repressing the NF-κB signaling pathway. J Med Virol, 2020: 20.
22. 劉亞萍, 趙倩, 殷燕, 等. 慢性乙型肝炎患者血清 GP73、HA 水平與 HBV DNA 載量及肝功能的相關性研究. 臨床誤診誤治, 2019, 32(9): 48-53.
23. Deveci O, Kaplan I, Tekin R, et al. Prognostic value of Golgi P73 and beta 2-microglobulin in patients with viral hepatitis B. Acta Biochim Pol, 2020, 67(1): 7-14.
24. 馬玲玉, 甄一寧, 羅云萍, 等. gp73 在小鼠肝纖維化肝組織中的表達及機制. 基礎醫學與臨床, 2020, 40(6): 771-776.
25. 羅雙艷, 何穎. 慢性乙肝患者肝臟炎癥及纖維化的影響因素及其與血清高爾基體蛋白 73 的相關性. 醫學信息, 2021, 34(15): 5-8.
26. 姚明解, 王雷婕, 關貴文, 等. 血清高爾基體蛋白 73 在輔助診斷慢性乙型肝炎患者中度以上肝損傷中的應用. 臨床肝膽病雜志, 2018, 34(4): 755-759.
27. 包海林, 謝群. HBV DNA、AFP、GP73 在慢性乙型肝炎病情嚴重程度及肝纖維化診斷中的應用價值研究. 海南醫學院學報, 2019, 25(9): 700-703.
28. 潘俊均, 黃仙圣, 岑偉明, 等. 不同病毒載量慢性乙型肝炎患者血清 AFP 與 GGT 和 GP73 變化及其臨床意義. 熱帶醫學雜志, 2022, 22(2): 179-183.
29. 申文曉. 慢性 HBV 感染者血清 GP73 和 IL-6 水平與肝纖維化指標的相關性. 桂林: 桂林醫學院, 2019.
30. 王利公, 趙珊, 陶慧, 等. 血清 AFP、GP73 和 AFP-L3 聯合檢測在慢性乙型肝炎診斷中的價值. 國際檢驗醫學雜志, 2019, 40(21): 2625-2628, 2632.
31. 杜婷. 血清高爾基體蛋白 73 對 ALT 正常或輕度升高的慢性乙型肝炎病毒感染者肝臟病變的預測價值. 銀川: 寧夏醫科大學, 2021.
32. 胡蕾蕾. 血清指標在慢性乙型肝炎患者肝纖維化診斷中的應用價值. 醫藥論壇雜志, 2021, 42(22): 43-46.
33. 王磊. 血清 SF、RBP4、GP73、resistin 水平檢測在慢性乙型肝炎患者病情評估中的應用價值. 實驗與檢驗醫學, 2018, 36(5): 752-754.
34. 奚經巧, 林枝, 趙春, 等. 肝功能正常慢性乙肝患者肝組織 GP73 表達與纖維化及炎癥分級關系. 實用預防醫學, 2018, 25(9): 1125-1128.
35. 黃冠華. 血清 GP73、CTLA4 水平與慢性乙型肝炎患者肝纖維化程度的相關性. 中國實用醫刊, 2021, 48(14): 49-52.
36. Yang D, Yao M, Yan Y, et al. Deoxycholic acid upregulates serum Golgi protein 73 through activating NF-κB pathway and destroying Golgi structure in liver disease. Biomolecules, 2021, 11(2): 205.
37. 魯鳳民, 曾婉嘉, 文夏杰, 等. 慢性乙型肝炎抗病毒治療相關新型標志物及其臨床應用. 肝臟, 2019, 24(5): 483-486.
38. 范旭, 單珊, 劉立偉, 等. 血清高爾基糖蛋白 73 優于 APRI、FIB-4 對慢性 HBV 感染患者顯著纖維化的診斷. 現代消化及介入診療, 2020, 25(4): 529-532.
39. Cao Z, Li Z, Wang Y, et al. Assessment of serum Golgi protein 73 as a biomarker for the diagnosis of significant fibrosis in patients with chronic HBV infection. J Viral Hepat, 2017, 24(Suppl 1): 57-65.
40. Gatselis NK, Tornai T, Shums Z, et al. Golgi protein-73: a biomarker for assessing cirrhosis and prognosis of liver disease patients. World J Gastroenterol, 2020, 26(34): 5130-5145.
41. 馬世河, 劉文艷, 陳沖, 等. 血清 GP73 水平聯合腹部超聲檢查對慢性乙型肝炎肝纖維化程度的評估價值. 山東醫藥, 2022, 62(1): 25-29.
42. Wei M, Xu Z, Pan X, et al. Serum GP73 - an additional biochemical marker for liver inflammation in chronic HBV infected patients with normal or slightly raised ALT. Sci Rep, 2019, 9(1): 1170.
43. 姜娜, 李瑛, 王光東, 等. 慢性乙肝不同炎癥分級患者的肝功能、纖維化指標和 GP73 檢測及臨床意義. 海南醫學, 2019, 30(24): 3155-3158.
44. 許正鋸, 潘興南, 魏梅娟, 等. 慢性 HBV 感染者血清 GP73 水平與白細胞介素 6 含量的相關性. 肝臟, 2017, 22(2): 136-139.
45. 劉沁雨, 常越, 張文, 等. GP73 預測慢性乙型肝炎患者肝硬化進展研究. 武警醫學, 2020, 31(4): 317-323.
46. Liu T, Yao M, Liu S, et al. Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma. Oncotarget, 2017, 8(10): 16498-16506.
47. Yao M, Wang L, Leung PSC, et al. The clinical significance of GP73 in immunologically mediated chronic liver diseases: experimental data and literature review. Clin Rev Allergy Immunol, 2018, 54(2): 282-294.
48. Atilla A, Ta?k?n MH, Kazak Z, et al. GP73 level in patients with chronic hepatitis B: relationship with liver biopsy, levels of ALT, AST and HBV DNA. Indian J Pathol Microbiol, 2022, 65(1): 55-58.
49. 劉燕娜, 姚明解, 鄭素軍, 等. 血清高爾基體蛋白 73 在慢性肝病患者中的臨床應用. 中華肝臟病雜志, 2022, 30(1): 4-8.
50. 魏豐賢, 劉釗, 耿婕, 等. 高爾基體蛋白 73 與肝臟疾病的關系. 臨床肝膽病雜志, 2017, 33(8): 1595-1598.
51. 黎振威. 高爾基體蛋白 73 表達對 HBV 感染慢性肝病患者抗病毒治療后肝纖維化改善的預測價值. 銀川: 寧夏醫科大學, 2019.
52. 黨英男, 賈舒婷, 趙偉, 等. 慢性乙型肝炎患者血清 IL-17A、GP73 水平與肝功能指標及病情嚴重程度的關系分析. 現代生物醫學進展, 2020, 20(23): 4580-4584, 4570.
53. 程華, 鞠輝, 宋德順, 等. 慢性乙型肝炎患者血清血管生成素樣蛋白 2 和高爾基體蛋白 73 水平變化及其診斷顯著肝纖維化的效能分析. 實用肝臟病雜志, 2019, 22(4): 494-497.
54. Xia Y, Zhang Y, Shen M, et al. Golgi protein 73 and its diagnostic value in liver diseases. Cell Prolif, 2019, 52(2): e12538.

Previous Article
Research progress of correlation between gastric cancer and non-Helicobacter pylori gastric microbes
Next Article
Progress in the treatment of chronic viral hepatitis B

West China Medical Journal

Research progress of novel serum marker Golgi protein 73 in clinical diagnosis and treatment of chronic hepatitis B

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content